Despite pressure on overseas sales from the strong dollar that has put a crimp in pharmaceutical company profits, Amgen reiterated the 2015 forecast it provided in October for adjusted earnings of $9.05 to $9.40 per share on revenue of $20.8 billion to $21.3 billion. Amgen is less exposed to foreign exchange fluctuations than other large drugmakers as only about 25 percent of its sales come from outside the United States. Excluding items, Amgen earned $2.16 per share, topping analysts' average expectations by 11 cents, according to Thomson Reuters I/B/E/S. The results were helped by a research and development tax credit that came through in the quarter, adding about 10 cents per share to earnings, the company said.
via Business News http://ift.tt/1JZ8I5L
0 commentaires:
Enregistrer un commentaire